Esophageal Cancer: An Updated Surveillance Epidemiology and End Results Database Analysis
- PMID: 32284773
- PMCID: PMC7141161
- DOI: 10.14740/wjon1254
Esophageal Cancer: An Updated Surveillance Epidemiology and End Results Database Analysis
Abstract
Background: Esophageal cancer is the sixth leading cause of cancer-related deaths and the eighth most common cancer worldwide with a 5-year survival rate of less than 25%. Here we report the incidence, risk factors and treatment options that are available currently, and moving into the future.
Methods: We retrospectively analyzed the Surveillance Epidemiology and End Results (SEER) database made available by the National Cancer Institute in the USA. Specifically we extracted data from the years 2004 - 2015.
Results: In total we identified 23,804 patients with esophageal adenocarcinoma and 13,919 patients with esophageal squamous cell carcinoma. Males were at an increased risk of developing both types of esophageal cancer when compared to females. Most cases of adenocarcinoma were diagnosed as poorly differentiated grade III (42%), and most cases of squamous cell carcinoma were diagnosed as moderately differentiated grade II (39.5%). The most common stage of presentation for both adenocarcinoma (36.9%) and squamous cell (26.8%) carcinoma was stage IV. The worst outcomes for adenocarcinoma were noted with grade III tumors (hazard ratio (HR): 1.56, 95% confidence interval (CI): 1.44 - 1.68, P value: < 0.01), stage IV tumors (HR: 3.58, 95% CI: 3.33 - 3.85, P value: < 0.01) and those not treated with surgery (HR: 2.54, 95% CI: 2.44 - 2.65, P value: < 0.01). For squamous cell carcinoma, the worst outcomes were noted with grade III tumors (HR: 1.35, 95% CI: 1.23 - 1.49, P value: < 0.01), stage IV tumors (HR: 2.12, 95% CI: 1.94 - 2.32, P value: <0.01).
Conclusions: The incidence of esophageal adenocarcinoma in the USA is steadily on the rise. Conversely, the incidence of squamous cell carcinoma has been continually declining. While white males had an increased incidence of both types of esophageal cancer, a higher proportion of African Americans suffered from squamous cell carcinoma. Despite the wide spread use of proton pump inhibitors, adenocarcinoma continues to be a major public health concern.
Keywords: Adenocarcinoma; Chemotherapy; Esophageal cancer; Radiotherapy; Squamous cell carcinoma.
Copyright 2020, Then et al.
Conflict of interest statement
None of the authors have any financial conflict of interest.
Figures



Similar articles
-
Trends and outcomes in the use of surgery and radiation for the treatment of locally advanced esophageal cancer: a propensity score adjusted analysis of the surveillance, epidemiology, and end results registry from 1998 to 2008.Dis Esophagus. 2014 Sep-Oct;27(7):662-9. doi: 10.1111/dote.12123. Epub 2013 Aug 13. Dis Esophagus. 2014. PMID: 23937253 Free PMC article.
-
Trends in the incidence and survival of patients with esophageal cancer: A SEER database analysis.Thorac Cancer. 2020 May;11(5):1121-1128. doi: 10.1111/1759-7714.13311. Epub 2020 Mar 10. Thorac Cancer. 2020. PMID: 32154652 Free PMC article.
-
Prognostic implications of signet ring cell histology in esophageal adenocarcinoma.Cancer. 2013 Sep 1;119(17):3156-61. doi: 10.1002/cncr.28099. Epub 2013 May 29. Cancer. 2013. PMID: 23719932
-
20-Year Comparative Survival and Mortality of Cancer of the Stomach by Age, Sex, Race, Stage, Grade, Cohort Entry Time-Period, Disease Duration & Selected ICD-O-3 Oncologic Phenotypes: A Systematic Review of 157,258 Cases for Diagnosis Years 1973-2014: (SEER*Stat 8.3.4).J Insur Med. 2019;48(1):5-23. doi: 10.17849/insm-48-1-1-19.1. Epub 2019 Oct 14. J Insur Med. 2019. PMID: 31609640
-
A meta-analysis on surgery with or without postoperative radiotherapy to treat squamous cell esophageal carcinoma.Int J Surg. 2020 Aug;80:184-191. doi: 10.1016/j.ijsu.2020.06.046. Epub 2020 Jul 10. Int J Surg. 2020. PMID: 32659390 Review.
Cited by
-
Novel mechanism of immune evasion mediated by tumor-associated macrophages in esophageal squamous cell carcinoma.Thorac Cancer. 2020 Sep;11(9):2383-2384. doi: 10.1111/1759-7714.13549. Epub 2020 Jul 19. Thorac Cancer. 2020. PMID: 32686281 Free PMC article. No abstract available.
-
Mapping the adult human esophagus in vivo and in vitro.Development. 2022 Oct 15;149(20):dev200614. doi: 10.1242/dev.200614. Epub 2022 Oct 24. Development. 2022. PMID: 36278875 Free PMC article.
-
Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity.Front Pharmacol. 2022 Nov 16;13:1028692. doi: 10.3389/fphar.2022.1028692. eCollection 2022. Front Pharmacol. 2022. PMID: 36467103 Free PMC article.
-
Trends and Projections in National United States Health Care Spending for Gastrointestinal Malignancies (1996-2030).Gastroenterology. 2022 Apr;162(4):1098-1110.e2. doi: 10.1053/j.gastro.2021.12.244. Epub 2021 Dec 16. Gastroenterology. 2022. PMID: 34922947 Free PMC article.
-
HLX07 alone or combined with serplulimab, cisplatin and 5-fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study.Cancer Commun (Lond). 2024 Dec;44(12):1431-1443. doi: 10.1002/cac2.12621. Epub 2024 Oct 24. Cancer Commun (Lond). 2024. PMID: 39446605 Free PMC article. Clinical Trial.
References
LinkOut - more resources
Full Text Sources